Test

Molecular Genetic PML - RARA Transcrpit Qualitative Analysis - RT-PCR

₹18,500 ₹12,499
Save 32%

Test Code

MOG50

Also Known As

No data available

Test Parameters Included

No data available

Department

MOLECULAR GENETICS

Methodology

RT-PCR (Reverse Transcription Polymerase Chain Reaction)
This test specifically utilizes Reverse Transcription Polymerase Chain Reaction (RT-PCR). This is a qualitative assay, meaning its primary purpose is to determine the presence or absence of the PML-RARA fusion gene transcript (mRNA), rather than to precisely quantify its amount.
Principle of Qualitative RT-PCR for PML-RARA:
* RNA Extraction: Total RNA, including mRNA, is first isolated from the patient's whole blood or bone marrow sample.
* Reverse Transcription (RT): The extracted RNA is then converted into complementary DNA (cDNA) using an enzyme called reverse transcriptase. This step is essential because PCR amplifies DNA, not RNA.
* Polymerase Chain Reaction (PCR): The cDNA is then used as a template for PCR amplification. Specific primers are designed to bind only to the unique sequence formed by the fusion of the PML and RARA genes.
* Amplification: If the PML-RARA fusion transcript is present in the sample, these primers will facilitate the enzymatic creation of millions of copies of the specific fusion product.
* Detection: The amplified DNA product is typically detected through techniques like gel electrophoresis (visualizing a band of the expected size) or via probe-based methods that indicate presence.
* Internal Control: An internal control gene (e.g., ABL1, G6PD) is simultaneously amplified in the same reaction. This control confirms that the RNA extraction, reverse transcription, and PCR amplification steps were successful and that the sample is suitable for analysis, thus helping to prevent false-negative results due to technical issues or poor sample quality.
This method offers high sensitivity for detecting the PML-RARA fusion, making it a valuable tool for the initial diagnosis of Acute Promyelocytic Leukemia (APL). However, it does not provide the quantitative data needed for monitoring minimal residual disease (MRD), for which quantitative RT-PCR (RT-qPCR) is preferred.

Sample Required

Whole Blood (WB) / Bone Marrow Aspirate (BMA) collected in EDTA Vacutainer
* Approximately 3-5 mL of Whole Blood or 1-3 mL of Bone Marrow Aspirate is typically required.
* EDTA (lavender-top) tubes are the preferred anticoagulant as they are optimal for preserving nucleic acids.
* Samples must be collected and transported under specific conditions (e.g., refrigerated, not frozen) and ideally reach the laboratory within 48-72 hours of collection due to the inherent instability of RNA.

Preparation

Proper collection and handling of the sample are crucial for the accuracy and reliability of this molecular test, as RNA is inherently unstable. * No specific patient preparation is required (e.g., fa... Read more

Schedule Report

5 Days

Emergency Report

Yes

Frequently Asked Questions

No data available

Test Description

ALSO KNOWN AS:<br/> PML-RARA Qualitative RT-PCR<br/> APL Diagnostic PCR Test<br/> t(15;17) Fusion Transcript Detection<br/> PML-RARA Fusion Gene Presence Test<br/> Acute... Read more

Book This Test

Share this test

  • High-end laboratory & medical equipment.
  • Outstanding doctor team.
  • Personalized care & high-quality service.
  • Tailormade health screening packages.
T&C